David A. Tuveson
Built the pancreatic cancer organoid models now used to test drugs against a patient's own tumour.
Developed the first pancreatic ductal organoid models and the mouse models that defined stromal biology; his laboratory drives organoid pharmacotyping trials and is a Lustgarten Foundation leader.
| Title | Journal | Year |
|---|---|---|
| Organoid models of human and mouse ductal pancreatic cancer | Cell | 2015 |
| Organoid profiling identifies common responders to chemotherapy in pancreatic cancer | Cancer Discovery | 2018 |
Pages like this
not linked directly; found by shared links- PersonAndrew J. Aguirre
Shares Lustgarten Foundation, Patient-derived organoids, Pancreatic ductal adenocarcinoma.
- IdeaGrow each trial patient's tumour as organoids to decide which platform arm opens next
Shares PDAC organoid pharmacotyping, Functional (ex vivo) drug testing, Patient-derived organoids, Pancreatic ductal adenocarcinoma.
- PersonTobias Janowitz
Shares Cold Spring Harbor Laboratory, Pancreatic ductal adenocarcinoma.
- TechnologyOrganoid-guided therapy at scale
Shares PDAC organoid pharmacotyping, Functional (ex vivo) drug testing, Patient-derived organoids.
- IdeaA bone marrow niche on a chip to study human dormancy
Shares Functional (ex vivo) drug testing, Patient-derived organoids.
- PersonEileen M. O'Reilly
Shares Lustgarten Foundation, Pancreatic ductal adenocarcinoma.
- IdeaTest drugs on freshly cut slices of the patient's own tumour
Shares Functional (ex vivo) drug testing, Patient-derived organoids.
- IdeaZebrafish avatars for a drug answer within a week
Shares Functional (ex vivo) drug testing, Pancreatic ductal adenocarcinoma.